The FDA Clears C4 Therapeutics' Investigational New Drug Application For CFT8919 For Non-small Cell Lung Cancer; C4T Expects To Initiate Trials Outside Greater China After Betta Pharmaceuticals Concludes Phase 1 Dose Escalation Study In Greater China
The FDA Clears C4 Therapeutics' Investigational New Drug Application For CFT8919 For Non-small Cell Lung Cancer; C4T Expects To Initiate Trials Outside Greater China After Betta Pharmaceuticals Concludes Phase 1 Dose Escalation Study In Greater China
美國食品藥品管理局批准了 C4 Therapeutics 針對非小細胞肺癌的 CFT8919 的研究性新藥申請；在貝達製藥完成大中華區 1 期劑量遞增研究後，C4T 預計將在大中華區以外啓動試驗
The FDA Clears C4 Therapeutics' Investigational New Drug Application For CFT8919 For Non-small Cell Lung Cancer; C4T Expects To Initiate Trials Outside Greater China After Betta Pharmaceuticals Concludes Phase 1 Dose Escalation Study In Greater China
美國食品藥品管理局批准了 C4 Therapeutics 針對非小細胞肺癌的 CFT8919 的研究性新藥申請；在貝達製藥完成大中華區 1 期劑量遞增研究後，C4T 預計將在大中華區以外啓動試驗
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。